Rossari Targets 30%+ Exports as Margins Improve

Rossari Biotech Limited — Q2 & H1 FY27 Earnings Call (held Oct 19, 2026)

1. Overall Tone of Management: Optimistic

Management repeatedly emphasizes “very strong note”, “highest-ever quarterly revenue and EBITDA”, and “remain confident” in delivering “sustainable and profitable growth in medium to long term.”
Even while acknowledging headwinds (freight/logistics, raw material volatility, cautious demand), they frame them as manageable and point to margin/product-mix actions and capacity utilization as the path forward.

2. Key Themes from Management Commentary

Strong H1 execution and scale-up
Q2 FY27 revenue +19% YoY to Rs. 698 cr; EBITDA +21% YoY to Rs. 87 cr; both described as highest-ever.
H1 performance: Q2 and Q1 each around ~Rs. 700 cr vs ~Rs. 565 cr average per quarter in prior-year H1.
Broad-based growth across divisions
HPPC, Textile Specialty Chemicals, AHN growth: 24% / 24% / 19% in H1.
Export growth is highlighted as a key contributor (exports ~31% of Q2 revenue).
Margin improvement via product mix and rationalization
Gross margin 31.6%; EBITDA margin 12.5% in Q2.
Management attributes sequential margin improvement to “better product mix” and actions like “tail cutting” (cutting bottom-margin products).
Innovation + R&D ramp-up
New Rossari Global Research and Innovation Centre (Navi Mumbai) “steadily ramping up” to shorten idea-to-commercial scale.
Pipeline focus: biosurfactants, personal care ingredients, pharma excipients, agro formulations, oil & gas solutions; 70+ new products launched in FY26.
Capacity utilization as the central lever
Utilization: blended ~60%; new ethoxylation facility currently ~30%, with ramp expected as EO allocation improves.
They reiterate peak utilization timing: “about 2 years post commissioning” (peak targeted by end of FY28).
International expansion / KSA initiative progresses
Board approved leasing land for a greenfield KSA facility (via wholly owned subsidiary).
They emphasize long-term benefits: raw material access, proximity to demand centers, especially oil & gas.
Balance sheet and working capital improvement
Net debt reduced to Rs. 221 cr (from Rs. 248 cr in June 26 and Rs. 281 cr in Mar 26).
Working capital days improved to 86 days (from 97 days at FY26 end).

3. Q&A Analysis

Theme A: Exports growth—drivers, sustainability, and margin impact

Core questions
Why exports are rising (Q2 exports ~31%); which segments/geographies drive it; how high can export mix go.
Whether export growth is coming from higher-value products (e.g., oil & gas) and what margin differential exists vs domestic.
Management response
Exports driven mainly by HPPC and Textile.
Textile export growth supported by Thailand blending facility and new geographies (Southeast Asia, Africa, Latin America).
HPPC export growth: ~34% YoY and ~35% QoQ; major contributors include HPPC + textile.
Margin: they claim export and B2B EBITDA margins increasing every quarter; higher-margin products sold in export and domestic; “tail cutting” helped.
Export mix targets:
- H1 export share already 27%
- Target: end of this year at least 30%+ exports
Notable / evasive points
They do not provide exact product-level or margin-by-segment export vs domestic details (“don’t have exact details”).
They avoid committing to a specific quarterly export growth rate (“cannot tell… every quarter”).

Theme B: Non-core / B2C & institutional profitability and exit plans

Core questions
Will B2C/institutional turn EBITDA positive in next two quarters?
Plans for B2C sale; timing and rationale.
Management response
B2C “breaking even” this quarter after “portfolio rationalization” and low-margin product pruning.
Expectation: H2 EBITDA positive and full-year at least breakeven; aim to move out of B2C/non-core at “appropriate time and value.”
Notable / unusually strong
Clear near-term profitability target: “at least in the next two quarters… H2 should also be an EBITDA positive.”
Evasive
No concrete timeline/value for sale; remains conditional (“appropriate time and appropriate value”).

Theme C: Ethylene oxide (EO) availability, Dahej utilization, and Reliance timeline

Core questions
Utilization expectations for FY28/FY29; peak revenue support and asset turnover.
Whether EO supply is currently constrained; incremental EO from Reliance expansion.
Management response
Peak utilization expected by end of FY28 (≈2 years post commissioning).
Maintains target: “3x of the CAPEX value to be the peak sales revenue.”
EO constraint: hoping no EO constraints this quarter; Reliance expansion expected to come in 2–3 quarters.
Incremental EO: no confirmation on quantities; expecting Reliance expansion to kick in in first quarter of next financial year; confirmation hoped “in next couple of months.”
Evasive / risk signal
Repeated lack of confirmation on incremental EO quantities is a key uncertainty.

Theme D: Core margin compression—what drove it and how to get back above 15%

Core questions
Why core B2B EBITDA margin fell YoY (14.8% → 14.1%) despite 21% revenue growth.
What steps will restore margins above 15%.
Management response
Freight and logistics costs: freight element “almost doubled, tripled” vs prior periods; major driver of margin compression.
Raw material inflation (phenol etc.) also pressured; pass-through not complete because “not all customers are ready to absorb entire freight increase.”
For margin recovery: focus on freight management + product mix + ramp-up/operating leverage; pharma/aroma ramp expected to improve gross margins over time.
Notable
CFO pushed back on the analyst’s arithmetic, but then provided a direct explanation: freight + RM.

Theme E: KSA project timeline, capex, and commercialization

Core questions
Timeline for commercial operations; whether still outline phase.
Expected capex and returns/ROCE/payback.
Management response
Step-by-step approach:
- Board approval to explore → land leasing approval → initial site activities (fencing/boundary wall).
- Blueprint/financials to be finalized before next board approval.
They hope developments happen over 8–12 months, but no firm commercialization timeline yet.
Capex/returns: they explicitly say they will come back once project plan is finalized; currently only land leased.
Evasive
No quantitative capex, no ROCE/payback numbers provided.

Theme F: FY27 outlook—EBITDA/margin and revenue growth

Core questions
H2 EBITDA margin trajectory; whether FY27 EBITDA margin will be ~12%.
Revenue growth guidance given geopolitical/logistics uncertainty.
Management response
EBITDA guidance for FY27: “similar kind of EBITDA of around 12% plus/minus”.
Revenue: “initial assessment” suggests mid-teen to a little high-teen growth for year-end, but they stress difficulty due to uncertainty.
They refuse to “hazard a guess” on H2 shipments/logistics routes (Bab el-Mandeb/Hormuz) and insurance/container availability.
Notable
They provide explicit margin guidance but hedge revenue due to macro/logistics.

4. Guidance / Outlook

Explicit guidance (quantitative)

FY27 EBITDA margin: “around 12% plus/minus” (also reiterated that this year they expect similar EBITDA %).
Export mix target: “by the end of this year should be at least 30%+ of revenue” (Q2 already 31%).
FY27 revenue growth (range): “between mid-teen to a little high-teen numbers” for year-end (qualitative range, but still numeric band).
B2C/institutional profitability: aim for H2 EBITDA positive and full-year breakeven (qualitative but with time-bound expectation).
Utilization/peak timing: peak utilization targeted by end of FY28; new ethoxylation facility ramp expected as EO allocation improves.

Implicit signals (qualitative)

Margin recovery depends on:
freight normalization and customer pass-through,
operating leverage as utilization rises,
pharma/aroma approvals and ramp (slow gestation).
KSA commercialization is not yet scheduled; management is still in blueprint/financial finalization stage.
They are cautious about forecasting due to route disruption, insurance, container/ISO tank availability.

5. Standout Statements (direct / high-signal)

Performance & confidence
“Q2 FY27 revenue grew by 19%… marking our highest-ever quarterly revenue and EBITDA.”
“we remain confident of delivering sustainable and profitable growth in medium to long term.”
Margin drivers
“freight costs have almost doubled, tripled… That has significantly impacted our EBITDA margins.”
EO / utilization
“peak utilization will happen about 2 years post the assets coming into commissioning… by end of FY28.”
“we still stick to the target of 3x of the CAPEX value to be the peak sales revenue.”
B2C turnaround
“after many quarters, we saw this B2C business breaking even… H2 should also be an EBITDA positive.”
Forecasting discipline
“we don’t want to hazard a guess… there are so many things beyond our control.”
KSA timeline uncertainty
“Once we have the entire blueprint… and the financial… done, we will go back to the Board” (no commercialization date yet).

6. Red Flags / Positive Signals

Red flags
– EO allocation uncertainty: “no confirmation” on incremental quantities from Reliance; EO availability remains a key swing factor.
– Freight/logistics volatility is explicitly called out as a major margin headwind; management admits not all customers absorb freight increases.
– KSA commercialization not time-bound; capex/returns not disclosed yet—could delay value realization.
– Forecast hedging: management repeatedly refuses to “hazard a guess” for H2 due to route/insurance/container constraints.

Positive signals
– Working capital improvement (86 days) and net debt reduction (to Rs. 221 cr).
– B2C profitability inflection (breakeven this quarter; targeted EBITDA positive in H2).
– Export momentum visible in numbers (export share rising to 31% in Q2; target 30%+ by year-end).
– Product-mix actions (tail cutting, higher-margin focus) are linked to margin improvements.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

Current (Q2/H1 FY27): more confident/constructive—management highlights record quarter and provides clearer near-term margin guidance (~12%).
Prior Q1 FY27 (Jul 20, 2026): optimistic but more focused on ramp-up and “wait and see” on margins; less explicit on export mix targets.
Prior Q4/FY26 (Apr 28, 2026): cautious on margins (12%–13% range) and emphasized cost environment; less “record” framing.
Shift classification: More Optimistic
More willingness to give specific targets (export share 30%+, FY27 EBITDA margin ~12%).
Still cautious on macro, but less defensive than earlier periods.

b. Tracking Past Commitments vs Outcomes

1) B2C/institutional exit / breakeven
– Past statement (Q1 FY27, Jul 20 2026): management expected calibrated steps; losses moderating; breakeven/profitability implied for FY27.
– Current outcome: B2C “breaking even” in Q2 FY27; expects H2 EBITDA positive and full-year breakeven.
– Flag: ✅ Delivered / On track (breakeven achieved earlier than “later” implied in earlier calls).

2) Margin improvement timeline
– Past statement (Q1 FY27): margins should improve as utilization improves and low-margin businesses exit; “base level” around 11.6% EBITDA margin.
– Current: EBITDA margin improved sequentially to 12.5% in Q2; but core margin YoY compressed due to freight/RM.
– Flag: ⏳ Partially delivered (sequential improvement, but YoY core margin not yet above prior levels).

3) EO constraint easing
– Past statement (Q1 FY27): EO availability expected to improve; “hopefully” by end of Q2/Q3.
– Current: still uncertainty—hoping no constraints this quarter; Reliance incremental quantities not confirmed.
– Flag: ⏳ Delayed / still uncertain (constraint risk persists).

4) KSA project progression
– Past statement (Q3 FY26 / Q4 FY26): in-principle approval and evaluation; no land lease or commercialization timeline.
– Current: board approved leasing land; still no capex/timeline.
– Flag: ✅ Progressed (milestone achieved) but ⏳ commercialization not yet delivered.

c. Narrative Shifts

Exports narrative strengthened: earlier calls discussed export growth; now they provide explicit export share targets and tie growth to Thailand facility + new geographies.
Margin narrative shifts from “product mix only” to “freight as primary driver”: current call more candid that freight/logistics is the key reason core margins compressed YoY.
B2C narrative becomes more actionable: from “calibrated steps” to breakeven achieved and H2 profitability expectation.

d. Consistency & Credibility Signals

Credibility: Medium
Positive: management connects margin changes to specific cost drivers (freight, RM) and provides measurable balance sheet improvements.
Concern: repeated lack of confirmation on EO incremental quantities and KSA commercialization/capex details reduces forecast reliability.
They avoid overpromising on H2 revenue due to macro uncertainty—this restraint supports credibility.

e. Evolution of Key Themes

Demand/macro: remains cautious; now explicitly tied to logistics route risks and insurance/container availability.
Margins: from “capacity utilization + mix” to “freight/RM pass-through limits” as a dominant near-term factor.
Expansion: KSA moved from “in-principle” to “land lease,” but still pre-blueprint on capex/returns.
Working capital: consistently improving—now quantified with days and net debt reduction.

f. Additional Insights (Cross-Period Intelligence)

A risk is building quietly: freight volatility is now repeatedly cited as margin-damaging even when exports grow—suggesting that top-line growth may not automatically translate into margin expansion until logistics stabilizes.
EO availability remains the swing variable: despite record revenue/EBITDA, management still cannot lock incremental EO quantities—meaning utilization and margin upside could be delayed.
B2C turnaround appears real (breakeven), but management still frames exit as conditional—so upside may depend on execution of rationalization/sale rather than only operational improvements.